Author

Kacey Anderson

Observed name: K. Anderson

Observed institutions: University of Pittsburgh, Gilead Sciences (United States)

OpenAlex ID: A5077361663

Filgotinib: A Clinical Pharmacology Review

2022 · Florence Namour, Kacey Anderson, et al. · Clinical Pharmacokinetics · 60

TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trial

2025 · Mazen Noureddin, Naim Alkhouri, et al. · Nature Medicine · 21

The Relative Bioavailability and Effects of Food and Acid‐Reducing Agents on Filgotinib Tablets in Healthy Subjects

2019 · Kacey Anderson, Hao Zheng, et al. · Clinical Pharmacology in Drug Development · 21

Assessment of the Effect of Filgotinib on the Pharmacokinetics of Atorvastatin, Pravastatin, and Rosuvastatin in Healthy Adult Participants

2021 · Kacey Anderson, Cara H. Nelson, et al. · Clinical Pharmacology in Drug Development · 15

Lack of Drug‐Drug Interaction Between Filgotinib, a Selective JAK1 Inhibitor, and Oral Hormonal Contraceptives Levonorgestrel/Ethinyl Estradiol in Healthy Volunteers

2020 · Rebecca Begley, Kacey Anderson, et al. · Clinical Pharmacology in Drug Development · 14

Exposure‐response relationships for the efficacy and safety of filgotinib and its metabolite GS‐829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies

2022 · Amy Meng, Kacey Anderson, et al. · British Journal of Clinical Pharmacology · 12

Evaluation of the potential drug interactions mediated through P‐gp, OCT2, and MATE1/2K with filgotinib in healthy subjects

2021 · Chia‐Hsiang Hsueh, Kacey Anderson, et al. · Clinical and Translational Science · 9

Filgotinib, a JAK1 Inhibitor, Has No Effect on QT Interval in Healthy Subjects

2019 · Kacey Anderson, Yan Xin, et al. · Clinical Pharmacology in Drug Development · 9

Thu0117 Pharmacokinetics and Short-term Safety of Filgotinib, a Selective Janus Kinase 1 Inhibitor, in Subjects With Moderate Hepatic Impairment

2019 · Kacey Anderson, Hao Zheng, et al. · Annals of the Rheumatic Diseases · 6

Pos0672 First-in-human Study of Gs-5718, an Oral Irak-4 Inhibitor, in Healthy Subjects: Pharmacokinetics, Safety, Tolerability, and Assessment of Effect of Food and Acid Reducing Agents on Exposure

2021 · K. Anderson, C.H. Hsueh, et al. · Annals of the Rheumatic Diseases · 4

CML-396 Safety, Tolerability, Pharmacokinetics, and the Effect of Food on TERN-701, an Oral Allosteric BCR-ABL Tyrosine Kinase Inhibitor, in Healthy Participants

2024 · Kacey Anderson, Leanne Holes, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

Ab0259 Evaluation of the Effect of Filgotinib on the Pharmacokinetics of Rosuvastatin, Atorvastatin, and Pravastatin

2021 · K. Anderson, C. Nelson, et al. · Annals of the Rheumatic Diseases · 1

Sat0149 Exposure-response Relationships for Efficacy and Safety of Filgotinib and Its Metabolite Gs-829845 in Subjects With Rheumatoid Arthritis Based on Phase 2 and Phase 3 Studies

2020 · A. Meng, K. Anderson, et al. · Annals of the Rheumatic Diseases · 1

POSTER: CML-586 Effect of TERN-701 on Transporter and Cytochrome P450 Probe Substrates and the Effect of Acid-Reducing Agents on TERN-701 Pharmacokinetics

2025 · Kacey Anderson, T Marmon, et al. · Clinical Lymphoma Myeloma & Leukemia

CML-586: Effect of TERN-701 on Transporter and Cytochrome P450 Probe Substrates and the Effect of Acid-Reducing Agents on TERN-701 Pharmacokinetics

2025 · Kacey Anderson, T Marmon, et al. · Clinical Lymphoma Myeloma & Leukemia

Safety, Tolerability, Pharmacokinetics, and the Effect of Food on TERN-701, an Oral Allosteric BCR-ABL Tyrosine Kinase Inhibitor, in Healthy Participants

2024 · Kacey Anderson, Leanne Holes, et al. · Clinical Lymphoma Myeloma & Leukemia

2014 · Kacey Anderson, Shea Liput, et al. · Critical Care Medicine

Age related pharmacokinetic and pharmacodynamic response of intranasal rGM-CSF (P4190)

2013 · Erin Resetar, Katherine Eichinger, et al. · The Journal of Immunology

Works count: 18

Citation count: 174

H-index: 8

I10-index: 6